<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Forest Laboratories Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/forest-laboratories-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Fri, 17 May 2013 21:09:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.1</generator>
		<item>
		<title>(FRX) Forest Laboratories Sees Positive Data on Combo Drug</title>
		<link>http://www.stockbloghub.com/2013/05/07/frx-forest-laboratories-sees-positive-data-on-combo-drug/135629</link>
		<comments>http://www.stockbloghub.com/2013/05/07/frx-forest-laboratories-sees-positive-data-on-combo-drug/135629#comments</comments>
		<pubDate>Tue, 07 May 2013 21:22:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Catalyst Pharmaceutical Partners Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CPRX]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=135629</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and Almirall, S.A. recently announced positive top-line data on their chronic obstructive pulmonary disease (COPD) fixed dose combination candidate, aclidinium bromide (LAMA) and formoterol fumarate (LABA). Two fixed dose combinations – aclidinium/formoterol (400/6mcg and 400/12mcg given twice a day) – were evaluated in the six month pivotal phase III study named AUGMENT COPD. Results showed that both combinations achieved a statistically significant improvement in the co-primary endpoints compared to placebo. Forest Labs said that both doses were found to be well-tolerated with common adverse events including cough, headache, urinary tract infection and back pain among others. Aclidinium/formoterol was administered using Almirall’s inhaler Genuair (US trade name: Pressair) The results presented from this study were consistent with results presented last month from another pivotal phase III study ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/05/07/frx-forest-laboratories-sees-positive-data-on-combo-drug/135629/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Pharma &amp; Biotech Stock Outlook &#8211; Apr 2013 &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2013/04/07/mrk-pharma-biotech-stock-outlook-apr-2013-zacks-analyst-interviews/132525</link>
		<comments>http://www.stockbloghub.com/2013/04/07/mrk-pharma-biotech-stock-outlook-apr-2013-zacks-analyst-interviews/132525#comments</comments>
		<pubDate>Sun, 07 Apr 2013 18:52:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AFFY]]></category>
		<category><![CDATA[Affymax Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JAZZ]]></category>
		<category><![CDATA[Jazz Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[OSIR]]></category>
		<category><![CDATA[Osiris Therapeutics Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=132525</guid>
		<description><![CDATA[The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa losing patent protection. These products alone represented branded sales worth more than $15 billion. However, the effect of the genericization of these products was felt mostly in 2012. While the industry won’t be completely free from genericization, the major patent expiries are over and done with. New products should start contributing significantly to results and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector. Some products that are slated to lose patent protection in 2013 include: Collaborations and Acquisitions The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/04/07/mrk-pharma-biotech-stock-outlook-apr-2013-zacks-analyst-interviews/132525/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Synergy Pharmaceuticals Shows Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2013/01/01/frx-synergy-pharmaceuticals-shows-pipeline-progress/125096</link>
		<comments>http://www.stockbloghub.com/2013/01/01/frx-synergy-pharmaceuticals-shows-pipeline-progress/125096#comments</comments>
		<pubDate>Wed, 02 Jan 2013 00:39:45 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=125096</guid>
		<description><![CDATA[Synergy Pharmaceuticals (SGYP) recently initiated a phase IIb study with plecanatide for the treatment of patients suffering from constipation-predominant irritable bowel syndrome (IBS-C). Synergy Pharma will be enrolling 350 patients suffering from IBS-C around 70 sites in the US. These patients will be treated with any one of the four doses of plecanatide (0.3, 1.0, 3.0, or 9.0 mg) or placebo for 12 weeks. The trial will be evaluating the average change in complete spontaneous bowel movements (CSBM&#8217;s) during the trial period in comparison to their baseline weekly CSBM rate that was established during the screening phase of the study. In addition to this, Synergy Pharma will be evaluating spontaneous bowel movements (SBM&#8217;s) and daily abdominal pain, discomfort along with bloating scores and impact of the candidate on disease-specific quality ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/01/01/frx-synergy-pharmaceuticals-shows-pipeline-progress/125096/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Pharmaceuticals and Biotech Stock Outlook &#8211; December 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/12/07/mrk-pharmaceuticals-and-biotech-stock-outlook-december-2012-industry-outlook/122969</link>
		<comments>http://www.stockbloghub.com/2012/12/07/mrk-pharmaceuticals-and-biotech-stock-outlook-december-2012-industry-outlook/122969#comments</comments>
		<pubDate>Fri, 07 Dec 2012 22:19:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BioSpecifics Technologies Corporation]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[BSTC]]></category>
		<category><![CDATA[Catalyst Pharmaceutical Partners Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CPRX]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GAIN]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Gladstone Investment Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JAZZ]]></category>
		<category><![CDATA[Jazz Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[W&T Offshore Inc]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[WTI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=122969</guid>
		<description><![CDATA[The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa losing patent protection. These products alone represented branded sales worth more than $15 billion. However, the effect of the genericization of these products will be felt mostly in 2012. While the industry won’t be completely free from genericization, the major patent expiries are over and done with. New products should start contributing significantly to results and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector. M&#38;A Activity The M&#38;A activity witnessed in the pharma sector in the last couple of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/12/07/mrk-pharmaceuticals-and-biotech-stock-outlook-december-2012-industry-outlook/122969/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Zinforo Gets European Commission Approval</title>
		<link>http://www.stockbloghub.com/2012/08/31/azn-astrazenecas-zinforo-gets-european-commission-approval/110964</link>
		<comments>http://www.stockbloghub.com/2012/08/31/azn-astrazenecas-zinforo-gets-european-commission-approval/110964#comments</comments>
		<pubDate>Fri, 31 Aug 2012 14:26:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CAI International Inc.]]></category>
		<category><![CDATA[CAP]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=110964</guid>
		<description><![CDATA[AstraZeneca (AZN) recently announced that the European Commission (EC) has approved Zinforo (ceftaroline fosamil) for treating adults with complicated skin and soft tissue infections (cSSTI) or community acquired pneumonia (CAP). The European approval did not come as a surprise as Zinforo had earlier received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Approval was based on encouraging data from four phase III trials &#8211; CANVAS 1 and 2 (cSSTI) and FOCUS 1 and 2 (CAP). While we are pleased with the European approval of Zinforo, we note that the market is highly competitive given the presence of players like Cubist Pharmaceutical’s (CBST) Cubicin and Pfizer’s (PFE) Tygacil. We note that in 2009, Forest Laboratories (FRX) had out-licensed co-exclusive development ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/31/azn-astrazenecas-zinforo-gets-european-commission-approval/110964/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNOV) MediciNova&#8217;s MN-221 Yields Positive Data</title>
		<link>http://www.stockbloghub.com/2012/08/26/mnov-medicinovas-mn-221-yields-positive-data/110239</link>
		<comments>http://www.stockbloghub.com/2012/08/26/mnov-medicinovas-mn-221-yields-positive-data/110239#comments</comments>
		<pubDate>Sun, 26 Aug 2012 22:01:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MediciNova Inc]]></category>
		<category><![CDATA[MNOV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=110239</guid>
		<description><![CDATA[MediciNova, Inc. (MNOV) recently announced positive preliminary results on intravenous MN-221 (bedoradrine). The randomized, placebo-controlled phase Ib trial evaluated the efficacy and safety of MN-221 in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD). As per preliminary data from the phase Ib trial, MN-221 demonstrated moderately improved pulmonary function compared to placebo. The data indicated an encouraging pharmacokinetic and efficacy profile. There were no significant safety concerns associated with the use of the candidate. Currently approved COPD treatments include Forest Laboratories, Inc.’s (FRX) Daliresp and GlaxoSmithKline’s (GSK) Advair. MediciNova is developing MN-221, a highly selective beta(2)-adrenergic receptor agonist, for the treatment of acute exacerbations of asthma and COPD. In 2004, MediciNova licensed exclusive rights to MN-221 from Kissei Pharmaceutical Co., Ltd. in all territories except Japan. Earlier, in May ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/26/mnov-medicinovas-mn-221-yields-positive-data/110239/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharma and Biotech Stock Outlook &#8211; August 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/08/10/pfe-pharma-biotech-stock-outlook-august-2012-industry-outlook/108031</link>
		<comments>http://www.stockbloghub.com/2012/08/10/pfe-pharma-biotech-stock-outlook-august-2012-industry-outlook/108031#comments</comments>
		<pubDate>Fri, 10 Aug 2012 18:00:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics Inc.]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cardiome Pharma Corporation]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CRME]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GAIN]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Gladstone Investment Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals Inc.]]></category>
		<category><![CDATA[SPPI]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[United Therapeutics Corporation]]></category>
		<category><![CDATA[UTHR]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=108031</guid>
		<description><![CDATA[The pharmaceutical industry is in the midst of one of the biggest patent cliffs with Pfizer’s (PFE) multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November 2011. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa. These products alone represented branded sales worth more than $15 billion. Another product that will start facing generic competition shortly is Merck’s (MRK) blockbuster Singulair. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. While generics will eat into sales, new products are not expected to generate the same level of sales as products losing patent protection. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/10/pfe-pharma-biotech-stock-outlook-august-2012-industry-outlook/108031/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Active on the Generics Front</title>
		<link>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937</link>
		<comments>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937#comments</comments>
		<pubDate>Mon, 09 Apr 2012 18:03:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97937</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s generic versions of Sanofi’s (SNY) high blood pressure drugs, Avapro and Avalide, AstraZeneca’s (AZN) schizophrenia treatment, Seroquel, and Forest Laboratories’ (FRX) Lexapro. While Teva will enjoy a 180-day period of marketing exclusivity where the generic launches of Avapro, Avalide and Lexapro are concerned, we note that other generic players like Dr. Reddy’s Laboratories (RDY) and Mylan (MYL) have also launched their generic versions of Seroquel. As per IMS data, annual US sales of Avapro, Avalide, Seroquel, and Lexapro were $464 million, $124 million, $4.6 billion and $2.9 billion, respectively. Teva also launched its authorized generic of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories and Janssen Pharmaceutica Sue Generic Players</title>
		<link>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647</link>
		<comments>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647#comments</comments>
		<pubDate>Tue, 20 Mar 2012 02:16:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=95647</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and Janssen Pharmaceutica NV, a Johnson &#38; Johnson (JNJ) company, recently filed a joint lawsuit against several generic companies that are looking to launch their generic versions of Bystolic (nebivolol). The patent infringement lawsuit has been filed in the US District Court for the District of Delaware for infringement of US Patent No. 6,545,040. The lawsuit has been filed against companies like Amerigen Pharmaceuticals, Inc., Glenmark Generics, Inc., Hetero USA Inc., Torrent Pharmaceuticals Ltd., Watson Laboratories, Inc. (WPI). Another patent infringement lawsuit has been filed by Forest Labs and Janssen in the US District Court for the Northern District of Illinois against Alkem Laboratories Limited and Indchemie Health Specialties Pvt. Ltd. This lawsuit is also related to the infringement of the ‘040 patent. With the lawsuits ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Earns Positive News on Pipeline</title>
		<link>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441</link>
		<comments>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441#comments</comments>
		<pubDate>Tue, 06 Mar 2012 21:31:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94441</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) recently reported back-to-back positive news on the pipeline front. The company and partner Gedeon Richter Plc. announced that their late-stage anti-psychotic candidate, cariprazine, met its primary endpoint in two phase III studies. The studies were conducted to evaluate cariprazine for the treatment of acute exacerbation of schizophrenia. Results showed that patients in the cariprazine arm achieved a significant improvement in symptom compared to patients in the placebo arm. Statistically significant separation from placebo was observed in all doses from week 2 and at each subsequent time point. Forest Labs and Gedeon said that the higher dose showed separation as early as week 1 of treatment.  The results were similar to data presented earlier from a phase IIb fixed-dose placebo-controlled study. Cariprazine is one of the candidates ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Learns of Positive Results on Gedeon Drug</title>
		<link>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536</link>
		<comments>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536#comments</comments>
		<pubDate>Tue, 14 Feb 2012 04:54:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91536</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and partner Gedeon Richter recently presented positive top-line results on their antipsychotic candidate, cariprazine (RGH-188). Preliminary top-line results were presented from a phase III study that was conducted in patients with acute mania associated with bipolar I disorder. Results from the five-week multi-center, double-blind, placebo-controlled, parallel-group study showed that patients in the cariprazine arm experienced significant symptom improvement compared to patients in the placebo arm. The improvement was observed as early as the fifth day of treatment and at each subsequent time point studied. Cariprazine, a novel, orally active D2/D3 antagonist, was generally well tolerated. However, discontinuations due to adverse events were higher in the cariprazine arms compared to placebo. Forest Labs intends to analyze the data further. Results from this study were similar to those ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Provides In-Line 2012 Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/27/teva-teva-pharmaceutical-industries-provides-in-line-2012-outlook/89233</link>
		<comments>http://www.stockbloghub.com/2011/12/27/teva-teva-pharmaceutical-industries-provides-in-line-2012-outlook/89233#comments</comments>
		<pubDate>Wed, 28 Dec 2011 03:58:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89233</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line with expectations. While the Zacks Consensus Earnings Estimate, prior to the release of guidance, was $5.62, the Zacks Consensus Revenue Estimate was about $21.8 billion. The Cephalon acquisition is expected to boost 2012 earnings by 20-25 cents. Teva expects to generate $11 billion sales in the US with the EU and Rest of the World (RoW) generating sales of $6.6 billion and $4.4 billion, respectively. The major chunk of revenues ($11.8 billion) will be provided by the generics business. US Generics Biz to Rebound Teva’s US generics business, which has been performing below expectations over the past ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/27/teva-teva-pharmaceutical-industries-provides-in-line-2012-outlook/89233/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) A Busy Week Ahead &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152</link>
		<comments>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152#comments</comments>
		<pubDate>Mon, 17 Oct 2011 15:31:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Acacia Research Corporation]]></category>
		<category><![CDATA[Access National Corporation]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ACTG]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Alliance Financial Corporation]]></category>
		<category><![CDATA[ALNC]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[American River Bankshares]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amphenol Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMRB]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AN]]></category>
		<category><![CDATA[ANCX]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[APH]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[APOL]]></category>
		<category><![CDATA[Apollo Group Inc.]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[ASBC]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[Associated Banc-Corp]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATMI]]></category>
		<category><![CDATA[ATMI Inc.]]></category>
		<category><![CDATA[AutoNation Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BAS]]></category>
		<category><![CDATA[Basic Energy Services Inc.]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BB & T Corporation]]></category>
		<category><![CDATA[BBND]]></category>
		<category><![CDATA[BBT]]></category>
		<category><![CDATA[BGG]]></category>
		<category><![CDATA[BigBand Networks Inc]]></category>
		<category><![CDATA[BJ's Restaurants Inc.]]></category>
		<category><![CDATA[BJRI]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLDR]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[BOOT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[Bottomline Technologies Inc]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[Briggs & Stratton Corporation]]></category>
		<category><![CDATA[BRKL]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brookline Bancorp Inc]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Buffalo Wild Wings Inc.]]></category>
		<category><![CDATA[Builders FirstSource Inc]]></category>
		<category><![CDATA[BWLD]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CAKE]]></category>
		<category><![CDATA[Capital One Financial Corporation]]></category>
		<category><![CDATA[Cardinal Financial Corporation]]></category>
		<category><![CDATA[Cash America International Inc]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CB]]></category>
		<category><![CDATA[CBE]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CCK]]></category>
		<category><![CDATA[Central Valley Community Bancorp]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CFNL]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[Chipotle Mexican Grill Inc.]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CKH]]></category>
		<category><![CDATA[CLB]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[CMG]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[COF]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[COHU]]></category>
		<category><![CDATA[Cohu Inc]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Community Trust Bancorp Inc]]></category>
		<category><![CDATA[Complete Production Services Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Cooper Industries Limited]]></category>
		<category><![CDATA[Core Laboratories NV]]></category>
		<category><![CDATA[Covanta Holding Corporation]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CPX]]></category>
		<category><![CDATA[CREE]]></category>
		<category><![CDATA[Cree Inc.]]></category>
		<category><![CDATA[Crown Holdings Inc.]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSH]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CTBI]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[CVA]]></category>
		<category><![CDATA[CVB Financial Corporation]]></category>
		<category><![CDATA[CVBF]]></category>
		<category><![CDATA[CVCY]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[Cymer Inc.]]></category>
		<category><![CDATA[CYMI]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[Datalink Corporation]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Diamondrock Hospitality Company]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[Dominos Pizza Inc.]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[DPZ]]></category>
		<category><![CDATA[DRH]]></category>
		<category><![CDATA[DTLK]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[EastGroup Properties Inc]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[EDU]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGP]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELS]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[ENZ]]></category>
		<category><![CDATA[Enzo Biochem Inc]]></category>
		<category><![CDATA[EPAY]]></category>
		<category><![CDATA[Equity Lifestyles Properties Inc]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXPO]]></category>
		<category><![CDATA[Exponent Inc.]]></category>
		<category><![CDATA[F.N.B. Corporation]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[FFIN]]></category>
		<category><![CDATA[FHN]]></category>
		<category><![CDATA[Fidelity National Financial Inc]]></category>
		<category><![CDATA[Fifth Third Bancorp]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Financial Bankshares Inc]]></category>
		<category><![CDATA[First Horizon National Corporation]]></category>
		<category><![CDATA[First Niagara Financial Group Inc]]></category>
		<category><![CDATA[FITB]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flexsteel Industries Inc]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FLIR]]></category>
		<category><![CDATA[FLIR Systems Inc]]></category>
		<category><![CDATA[FLXS]]></category>
		<category><![CDATA[FNB]]></category>
		<category><![CDATA[FNF]]></category>
		<category><![CDATA[FNFG]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[Forward Air Corporation]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[FSI International Inc]]></category>
		<category><![CDATA[FSII]]></category>
		<category><![CDATA[FULT]]></category>
		<category><![CDATA[Fulton Financial Corporation]]></category>
		<category><![CDATA[FWRD]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[Gardner Denver Inc.]]></category>
		<category><![CDATA[GATX Corporation]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GDI]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Gentex Corporation]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GHL]]></category>
		<category><![CDATA[GLF]]></category>
		<category><![CDATA[GMT]]></category>
		<category><![CDATA[GNTX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[Greenhill & Co Inc.]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Gulfmark Offshore Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HA]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[HAR]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[Harman International Industries Inc]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[Hawaiian Holdings Inc.]]></category>
		<category><![CDATA[HBAN]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[HCBK]]></category>
		<category><![CDATA[HCCI]]></category>
		<category><![CDATA[Heartland Express Inc]]></category>
		<category><![CDATA[Heritage-Crystal Clean Inc]]></category>
		<category><![CDATA[HITT]]></category>
		<category><![CDATA[Hittite Microwave Corporation]]></category>
		<category><![CDATA[HNI]]></category>
		<category><![CDATA[HNI Corporation]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[HOMB]]></category>
		<category><![CDATA[Home Bancshares Inc (Conway AR)]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[HTLD]]></category>
		<category><![CDATA[HUBB]]></category>
		<category><![CDATA[Hubbell Inc B Shares]]></category>
		<category><![CDATA[Hudson City Bancorp Inc]]></category>
		<category><![CDATA[Huntington Bancshares Inc]]></category>
		<category><![CDATA[IBKR]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[ICU Medical Inc]]></category>
		<category><![CDATA[ICUI]]></category>
		<category><![CDATA[IDEX Corporation]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>
		<category><![CDATA[IEX]]></category>
		<category><![CDATA[IIIN]]></category>
		<category><![CDATA[INDB]]></category>
		<category><![CDATA[Independent Bank Corporation]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Infinera Corporation]]></category>
		<category><![CDATA[INFN]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[Insteel Industries Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Interactive Brokers Group Inc]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[Ixia]]></category>
		<category><![CDATA[JAKK]]></category>
		<category><![CDATA[JAKKS Pacific Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[Kensey Nash Corporation]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[Kinder Morgan Management LLC]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[KMR]]></category>
		<category><![CDATA[Knight Transportation Inc]]></category>
		<category><![CDATA[KNL]]></category>
		<category><![CDATA[Knoll Inc.]]></category>
		<category><![CDATA[KNSY]]></category>
		<category><![CDATA[KNX]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[Koninklijke Philips Electronics NV]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[Lacrosse Footwear Inc.]]></category>
		<category><![CDATA[Lakeland Bancorp Inc]]></category>
		<category><![CDATA[Lam Research Corporation]]></category>
		<category><![CDATA[Lare Holdings Inc]]></category>
		<category><![CDATA[LaSalle Hotel Properties]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LBAI]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LHO]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[Linear Technology Corporation]]></category>
		<category><![CDATA[LLTC]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[LNCR]]></category>
		<category><![CDATA[LRCX]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[LUV]]></category>
		<category><![CDATA[M&T Bank Corporation]]></category>
		<category><![CDATA[MAN]]></category>
		<category><![CDATA[MANH]]></category>
		<category><![CDATA[Manhattan Associates Inc.]]></category>
		<category><![CDATA[Manpower Inc.]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Mattson Technology Inc]]></category>
		<category><![CDATA[Maxim Integrated Products Inc]]></category>
		<category><![CDATA[Mb Financial Inc]]></category>
		<category><![CDATA[MBFI]]></category>
		<category><![CDATA[MBWM]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MCRI]]></category>
		<category><![CDATA[Mercantile Bank Corporation]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MHP]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKS Instruments Inc.]]></category>
		<category><![CDATA[MKSI]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[MNRO]]></category>
		<category><![CDATA[Monarch Casino & Resort Inc.]]></category>
		<category><![CDATA[Monro Muffler Brake Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MTB]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[MTSN]]></category>
		<category><![CDATA[MXIM]]></category>
		<category><![CDATA[MYE]]></category>
		<category><![CDATA[Myers Industries Inc.]]></category>
		<category><![CDATA[NBL]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[NetScout Systems Inc]]></category>
		<category><![CDATA[New Oriental Education & Technology Group]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[Newfield Exploration Company]]></category>
		<category><![CDATA[NFX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[Noble Energy Inc]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[NTCT]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVR]]></category>
		<category><![CDATA[NVR Inc.]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[OKSB]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[ORB]]></category>
		<category><![CDATA[Orbital Sciences Corporation]]></category>
		<category><![CDATA[Pacific Continental Corporation]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[Park National Corporation]]></category>
		<category><![CDATA[Parker Hannifin Corporation]]></category>
		<category><![CDATA[Patni Computer Systems Limited]]></category>
		<category><![CDATA[Patriot Coal Corporation]]></category>
		<category><![CDATA[PBCT]]></category>
		<category><![CDATA[PCBK]]></category>
		<category><![CDATA[PCX]]></category>
		<category><![CDATA[PDS]]></category>
		<category><![CDATA[PENN]]></category>
		<category><![CDATA[Penn National Gaming Inc.]]></category>
		<category><![CDATA[Peoples United Financial Inc]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PFBC]]></category>
		<category><![CDATA[PGI]]></category>
		<category><![CDATA[PH]]></category>
		<category><![CDATA[PHG]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Pinnacle Financial Partners Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[Pixelworks Inc]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[Platinum Underwriters Holdings Limited]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[PNFP]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[POOL]]></category>
		<category><![CDATA[Pool Corp]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[Precision Drilling Trust]]></category>
		<category><![CDATA[Preferred Bank]]></category>
		<category><![CDATA[Premiere Global Services Inc.]]></category>
		<category><![CDATA[PRK]]></category>
		<category><![CDATA[Prosperity Bancshares Inc.]]></category>
		<category><![CDATA[PRSP]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[PTP]]></category>
		<category><![CDATA[PXLW]]></category>
		<category><![CDATA[Rambus Inc.]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[RCKY]]></category>
		<category><![CDATA[Renaissance Learning Inc.]]></category>
		<category><![CDATA[Renasant Corporation]]></category>
		<category><![CDATA[RHI]]></category>
		<category><![CDATA[Riverbed Technology Inc.]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RLRN]]></category>
		<category><![CDATA[RMBS]]></category>
		<category><![CDATA[RNST]]></category>
		<category><![CDATA[Robert Half International Inc.]]></category>
		<category><![CDATA[ROC]]></category>
		<category><![CDATA[Rockwood Holdings Inc.]]></category>
		<category><![CDATA[Rocky Brands Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[RVBD]]></category>
		<category><![CDATA[Safe Bulkers Inc.]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SB]]></category>
		<category><![CDATA[SBCF]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[SCHN]]></category>
		<category><![CDATA[Schnitzer Steel Industries Inc]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[SCL]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seacoast Banking Corporation of Florida]]></category>
		<category><![CDATA[Seacor Holdings Inc.]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SEI Investments Company]]></category>
		<category><![CDATA[SEIC]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[Sensient Technologies Corporation]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[Shaw Communications Inc.]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[SIVB]]></category>
		<category><![CDATA[SJR]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SLM]]></category>
		<category><![CDATA[Slm Corporation]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[SONC]]></category>
		<category><![CDATA[Sonic Corporation]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[Southwest Airlines Company]]></category>
		<category><![CDATA[Southwest Bancorp Inc]]></category>
		<category><![CDATA[Spartan Stores Inc.]]></category>
		<category><![CDATA[SPTN]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[Stanley Black & Decker]]></category>
		<category><![CDATA[Stanley Furniture Company Inc]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[Stepan Company]]></category>
		<category><![CDATA[STI]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[STLY]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SunTrust Banks Inc.]]></category>
		<category><![CDATA[SUPERVALU Inc.]]></category>
		<category><![CDATA[SVB Financial Group]]></category>
		<category><![CDATA[SVU]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SXT]]></category>
		<category><![CDATA[SY Bancorp Inc.]]></category>
		<category><![CDATA[SYBT]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[SYNA]]></category>
		<category><![CDATA[Synaptics Inc]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCB]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TCF Financial Corporation]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[Temple-Inland Inc.]]></category>
		<category><![CDATA[Tempur Pedic International Inc]]></category>
		<category><![CDATA[TESS]]></category>
		<category><![CDATA[TESSCO Technologies Inc.]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[The Cheesecake Factory Incorporated]]></category>
		<category><![CDATA[The Chubb Corporation]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The McGraw-Hill Companies Inc]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Thomas & Betts Corporation]]></category>
		<category><![CDATA[TIN]]></category>
		<category><![CDATA[TNB]]></category>
		<category><![CDATA[TPX]]></category>
		<category><![CDATA[Tractor Supply Company]]></category>
		<category><![CDATA[Travelzoo Inc.]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSCO]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[TZOO]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[UBNK]]></category>
		<category><![CDATA[Ultratech Inc.]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[UNF]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[UniFirst Corporation]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[United Financial Bancorp]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USA Truck Inc.]]></category>
		<category><![CDATA[USAK]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[USG]]></category>
		<category><![CDATA[USG Corporation]]></category>
		<category><![CDATA[UTEK]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[Valley National Bancorp]]></category>
		<category><![CDATA[VCBI]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[Viad Corporation]]></category>
		<category><![CDATA[Virginia Commerce Bancorp Inc]]></category>
		<category><![CDATA[VLY]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[VVI]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WABC]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[Washington Federal Inc]]></category>
		<category><![CDATA[Waste Connections Inc.]]></category>
		<category><![CDATA[Watsco Inc.]]></category>
		<category><![CDATA[WCC]]></category>
		<category><![CDATA[WCN]]></category>
		<category><![CDATA[WD-40 Company]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[WDFC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WERN]]></category>
		<category><![CDATA[Werner Enterprises Inc.]]></category>
		<category><![CDATA[WESCO International Inc.]]></category>
		<category><![CDATA[Westamerica BanCorporation]]></category>
		<category><![CDATA[Westell Technologies Inc]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Westwood Holdings Group Inc]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WFSL]]></category>
		<category><![CDATA[WHG]]></category>
		<category><![CDATA[WNS]]></category>
		<category><![CDATA[WNS (Holdings) Limited]]></category>
		<category><![CDATA[WSO]]></category>
		<category><![CDATA[WSTL]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>
		<category><![CDATA[Xilinx Inc.]]></category>
		<category><![CDATA[XLNX]]></category>
		<category><![CDATA[XXIA]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85152</guid>
		<description><![CDATA[Earnings Preview 10/14/11 While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&#38;P 500. Thus, by the end of the week we will have a very good idea of how the overall season will go. Not only will there be a lot of reports, but many of those we get will be very important ones. The table at the end of this report reads like a who’s who of American industry, including: Apple (AAPL), American Express (AXP), Bank of America (BAC), Citigroup (C), General Electric (GE), Goldman Sachs (GS), IBM (IBM), Intel (INTC) and McDonald’s (MCD). And that&#8217;s just the first half of the alphabet! ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) 2011 Second Quarter Earnings Preview &#8211; Detailed</title>
		<link>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251</link>
		<comments>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251#comments</comments>
		<pubDate>Mon, 18 Jul 2011 21:09:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[ABB]]></category>
		<category><![CDATA[ABB Limited]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Acacia Research Corporation]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ACTG]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALB]]></category>
		<category><![CDATA[Albemarle Corporation]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[Altria Group Inc.]]></category>
		<category><![CDATA[ALV]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[AmeriServ Financial Inc]]></category>
		<category><![CDATA[Amphenol Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMSG]]></category>
		<category><![CDATA[AmSurg Corporation]]></category>
		<category><![CDATA[AMTD]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[APH]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AptarGroup Inc.]]></category>
		<category><![CDATA[ARB]]></category>
		<category><![CDATA[Arbitron Inc]]></category>
		<category><![CDATA[ASBC]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[ASRV]]></category>
		<category><![CDATA[Associated Banc-Corp]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT Cross Company]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATMI]]></category>
		<category><![CDATA[ATMI Inc.]]></category>
		<category><![CDATA[ATR]]></category>
		<category><![CDATA[ATX]]></category>
		<category><![CDATA[Autoliv Inc.]]></category>
		<category><![CDATA[AVID]]></category>
		<category><![CDATA[Avid Technology Inc]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BancFirst Corporation]]></category>
		<category><![CDATA[Banco Latinoamericano de Exportaciones SA]]></category>
		<category><![CDATA[Bancorp Rhode Island Inc]]></category>
		<category><![CDATA[BANF]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BARI]]></category>
		<category><![CDATA[BAS]]></category>
		<category><![CDATA[Basic Energy Services Inc.]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BB & T Corporation]]></category>
		<category><![CDATA[BBT]]></category>
		<category><![CDATA[BJ's Restaurants Inc.]]></category>
		<category><![CDATA[BJRI]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLDR]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BLX]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[BOOT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[BTU]]></category>
		<category><![CDATA[Builders FirstSource Inc]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[CA]]></category>
		<category><![CDATA[Ca Technologies]]></category>
		<category><![CDATA[CAKE]]></category>
		<category><![CDATA[Cardinal Financial Corporation]]></category>
		<category><![CDATA[Cash America International Inc]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CB]]></category>
		<category><![CDATA[CBE]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[CCK]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Celanese Corporation]]></category>
		<category><![CDATA[Celestica Inc.]]></category>
		<category><![CDATA[Cemex S.A.B. de C.V.]]></category>
		<category><![CDATA[Central Valley Community Bancorp]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CFNL]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[Chicago Bridge & Iron Company N.V.]]></category>
		<category><![CDATA[Chipotle Mexican Grill Inc.]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cintas Corporation]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CLB]]></category>
		<category><![CDATA[CLS]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[CMCO]]></category>
		<category><![CDATA[CMG]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[Coca-Cola FEMSA S.A.B de CV]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[COHU]]></category>
		<category><![CDATA[Cohu Inc]]></category>
		<category><![CDATA[COL]]></category>
		<category><![CDATA[Columbus Mckinnon Corporation]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Complete Production Services Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Cooper Industries Limited]]></category>
		<category><![CDATA[Core Laboratories NV]]></category>
		<category><![CDATA[Covanta Holding Corporation]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CPX]]></category>
		<category><![CDATA[Crown Holdings Inc.]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSH]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CTAS]]></category>
		<category><![CDATA[CVA]]></category>
		<category><![CDATA[CVB Financial Corporation]]></category>
		<category><![CDATA[CVBF]]></category>
		<category><![CDATA[CVCY]]></category>
		<category><![CDATA[CX]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[Cymer Inc.]]></category>
		<category><![CDATA[CYMI]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[DAL]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[Datalink Corporation]]></category>
		<category><![CDATA[Delta Air Lines Inc.]]></category>
		<category><![CDATA[DGII]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Digi International Inc.]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[DTLK]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[Eagle Bancorp Inc]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[Eastern Virginia Bankshares Inc]]></category>
		<category><![CDATA[EastGroup Properties Inc]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[EDR]]></category>
		<category><![CDATA[EDU]]></category>
		<category><![CDATA[Education Realty Trust Inc]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGBN]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGP]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[ELGX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELS]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[Endologix Inc]]></category>
		<category><![CDATA[Entegris Inc]]></category>
		<category><![CDATA[ENTG]]></category>
		<category><![CDATA[Equity Lifestyles Properties Inc]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[EVBS]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXPO]]></category>
		<category><![CDATA[Exponent Inc.]]></category>
		<category><![CDATA[EZCORP Inc.]]></category>
		<category><![CDATA[EZPW]]></category>
		<category><![CDATA[F5 Networks Inc.]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[FFIV]]></category>
		<category><![CDATA[Fidelity National Information Services Inc]]></category>
		<category><![CDATA[Fifth Third Bancorp]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Niagara Financial Group Inc]]></category>
		<category><![CDATA[FIS]]></category>
		<category><![CDATA[FITB]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FLIR]]></category>
		<category><![CDATA[FLIR Systems Inc]]></category>
		<category><![CDATA[FMX]]></category>
		<category><![CDATA[FNFG]]></category>
		<category><![CDATA[Fomento Economico Mexicano S.a.b De C.v.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[Forward Air Corporation]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[FULT]]></category>
		<category><![CDATA[Fulton Financial Corporation]]></category>
		<category><![CDATA[FWRD]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[Gardner Denver Inc.]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GDI]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Gentex Corporation]]></category>
		<category><![CDATA[GLF]]></category>
		<category><![CDATA[Glimcher Realty Trust]]></category>
		<category><![CDATA[Global Payments Inc]]></category>
		<category><![CDATA[GNTX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[Goodrich Corporation]]></category>
		<category><![CDATA[GPN]]></category>
		<category><![CDATA[GR]]></category>
		<category><![CDATA[GRT]]></category>
		<category><![CDATA[Grupo Aeroportuario Centro Norte S.A. de C.V.]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Gulfmark Offshore Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hancock Holding Company]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[HBAN]]></category>
		<category><![CDATA[HBHC]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[Healthways Inc]]></category>
		<category><![CDATA[Heartland Express Inc]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[HITT]]></category>
		<category><![CDATA[Hittite Microwave Corporation]]></category>
		<category><![CDATA[HNI]]></category>
		<category><![CDATA[HNI Corporation]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[HOMB]]></category>
		<category><![CDATA[Home Bancshares Inc (Conway AR)]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[Host Hotels & Resorts Inc.]]></category>
		<category><![CDATA[HST]]></category>
		<category><![CDATA[HTLD]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Huntington Bancshares Inc]]></category>
		<category><![CDATA[HWAY]]></category>
		<category><![CDATA[IBKR]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[ICU Medical Inc]]></category>
		<category><![CDATA[ICUI]]></category>
		<category><![CDATA[IDEX Corporation]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>
		<category><![CDATA[IEX]]></category>
		<category><![CDATA[IIIN]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Infinera Corporation]]></category>
		<category><![CDATA[INFN]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[Insteel Industries Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Interactive Brokers Group Inc]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[Ixia]]></category>
		<category><![CDATA[JAKK]]></category>
		<category><![CDATA[JAKKS Pacific Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JCI]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Johnson Controls Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[Kinder Morgan Management LLC]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[KMR]]></category>
		<category><![CDATA[KNL]]></category>
		<category><![CDATA[Knoll Inc.]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[KOF]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[Lacrosse Footwear Inc.]]></category>
		<category><![CDATA[Landstar System Inc.]]></category>
		<category><![CDATA[Lare Holdings Inc]]></category>
		<category><![CDATA[LaSalle Hotel Properties]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LECO]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LHO]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[Lincoln Electric Holdings]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[LNCR]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LSTR]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[M&T Bank Corporation]]></category>
		<category><![CDATA[MAN]]></category>
		<category><![CDATA[MANH]]></category>
		<category><![CDATA[Manhattan Associates Inc.]]></category>
		<category><![CDATA[Manpower Inc.]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Matthews International Corporation]]></category>
		<category><![CDATA[MATW]]></category>
		<category><![CDATA[Mb Financial Inc]]></category>
		<category><![CDATA[MBFI]]></category>
		<category><![CDATA[MBWM]]></category>
		<category><![CDATA[MCBI]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MCRI]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Mellanox Technologies Limited]]></category>
		<category><![CDATA[Mercantile Bank Corporation]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[Merit Medical Systems Inc]]></category>
		<category><![CDATA[Metrocorp Bancshares Inc.]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKS Instruments Inc.]]></category>
		<category><![CDATA[MKSI]]></category>
		<category><![CDATA[MLNX]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[MMSI]]></category>
		<category><![CDATA[MNRO]]></category>
		<category><![CDATA[MO]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[Monarch Casino & Resort Inc.]]></category>
		<category><![CDATA[Monro Muffler Brake Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MOS]]></category>
		<category><![CDATA[Mosaic Company]]></category>
		<category><![CDATA[MOSY]]></category>
		<category><![CDATA[MoSys Inc]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MTB]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[MYE]]></category>
		<category><![CDATA[Myers Industries Inc.]]></category>
		<category><![CDATA[NAFC]]></category>
		<category><![CDATA[Nash FInch Company]]></category>
		<category><![CDATA[NCR]]></category>
		<category><![CDATA[NCR Corporation]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[NetScout Systems Inc]]></category>
		<category><![CDATA[New Oriental Education & Technology Group]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[Newfield Exploration Company]]></category>
		<category><![CDATA[NFX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NTCT]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVR]]></category>
		<category><![CDATA[NVR Inc.]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[OFG]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[Olin Corporation]]></category>
		<category><![CDATA[OLN]]></category>
		<category><![CDATA[OMAB]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[Oriental Financial Group Inc.]]></category>
		<category><![CDATA[Pacific Continental Corporation]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[PAG]]></category>
		<category><![CDATA[Park National Corporation]]></category>
		<category><![CDATA[PBCT]]></category>
		<category><![CDATA[PCBK]]></category>
		<category><![CDATA[PCP]]></category>
		<category><![CDATA[PDS]]></category>
		<category><![CDATA[Peabody Energy Corporation]]></category>
		<category><![CDATA[PENN]]></category>
		<category><![CDATA[Penn National Gaming Inc.]]></category>
		<category><![CDATA[Penske Automotive Group Inc.]]></category>
		<category><![CDATA[Peoples United Financial Inc]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[Pepsico Inc.]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PGI]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Pinnacle Financial Partners Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[Platinum Underwriters Holdings Limited]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[Plexus Corporation]]></category>
		<category><![CDATA[PLXS]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMC-Sierra Inc.]]></category>
		<category><![CDATA[PMCS]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[PNFP]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[POOL]]></category>
		<category><![CDATA[Pool Corp]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[Precision Castparts Corporation]]></category>
		<category><![CDATA[Precision Drilling Trust]]></category>
		<category><![CDATA[Premiere Global Services Inc.]]></category>
		<category><![CDATA[PRK]]></category>
		<category><![CDATA[Prosperity Bancshares Inc.]]></category>
		<category><![CDATA[PRSP]]></category>
		<category><![CDATA[PTP]]></category>
		<category><![CDATA[QCOM]]></category>
		<category><![CDATA[QUALCOMM Inc]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[RAI]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[Renaissance Learning Inc.]]></category>
		<category><![CDATA[Renasant Corporation]]></category>
		<category><![CDATA[Reynolds American Inc.]]></category>
		<category><![CDATA[RHI]]></category>
		<category><![CDATA[Riverbed Technology Inc.]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RLRN]]></category>
		<category><![CDATA[RNST]]></category>
		<category><![CDATA[Robert Half International Inc.]]></category>
		<category><![CDATA[Rockwell Collins Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[RT]]></category>
		<category><![CDATA[Ruby Tuesday Inc.]]></category>
		<category><![CDATA[RVBD]]></category>
		<category><![CDATA[SABA]]></category>
		<category><![CDATA[Saba Software Inc.]]></category>
		<category><![CDATA[Safeway Inc.]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SBIB]]></category>
		<category><![CDATA[Schiff Nutrition International Inc]]></category>
		<category><![CDATA[SCHL]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[Scholastic Corporation]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SEI Investments Company]]></category>
		<category><![CDATA[SEIC]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[Sensient Technologies Corporation]]></category>
		<category><![CDATA[SFG]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[Sherwin-Williams Company]]></category>
		<category><![CDATA[SHW]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[Skyworks Solutions Inc.]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SLM]]></category>
		<category><![CDATA[Slm Corporation]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[StanCorp Financial Group Inc.]]></category>
		<category><![CDATA[Stanley Black & Decker]]></category>
		<category><![CDATA[Stanley Furniture Company Inc]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[Sterling Bancshares Inc]]></category>
		<category><![CDATA[STI]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[STLY]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SunTrust Banks Inc.]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SWKS]]></category>
		<category><![CDATA[SWY]]></category>
		<category><![CDATA[SXT]]></category>
		<category><![CDATA[SY Bancorp Inc.]]></category>
		<category><![CDATA[SYBT]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TAYC]]></category>
		<category><![CDATA[Taylor Capital Group Inc]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCB]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TCF Financial Corporation]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[TD AMERITRADE Holding Corporation]]></category>
		<category><![CDATA[TEL]]></category>
		<category><![CDATA[Temple-Inland Inc.]]></category>
		<category><![CDATA[Terex Corporation]]></category>
		<category><![CDATA[TESS]]></category>
		<category><![CDATA[TESSCO Technologies Inc.]]></category>
		<category><![CDATA[TEX]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[The Cheesecake Factory Incorporated]]></category>
		<category><![CDATA[The Chubb Corporation]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Thomas & Betts Corporation]]></category>
		<category><![CDATA[TIN]]></category>
		<category><![CDATA[TNB]]></category>
		<category><![CDATA[Tractor Supply Company]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSCO]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[Tyco Electronics Limited]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[UBNK]]></category>
		<category><![CDATA[Ultratech Inc.]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[United Financial Bancorp]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[UTEK]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[VCBI]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>
		<category><![CDATA[Virginia Commerce Bancorp Inc]]></category>
		<category><![CDATA[Vitran Corp Inc]]></category>
		<category><![CDATA[VIVO]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[VTNC]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WABC]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[Waste Connections Inc.]]></category>
		<category><![CDATA[Watsco Inc.]]></category>
		<category><![CDATA[WCC]]></category>
		<category><![CDATA[WCN]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WERN]]></category>
		<category><![CDATA[Werner Enterprises Inc.]]></category>
		<category><![CDATA[WESCO International Inc.]]></category>
		<category><![CDATA[Westamerica BanCorporation]]></category>
		<category><![CDATA[Westell Technologies Inc]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Westwood Holdings Group Inc]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WHG]]></category>
		<category><![CDATA[Whirlpool Corporation]]></category>
		<category><![CDATA[WHR]]></category>
		<category><![CDATA[Wipro Limited]]></category>
		<category><![CDATA[WIT]]></category>
		<category><![CDATA[WNI]]></category>
		<category><![CDATA[WNS]]></category>
		<category><![CDATA[WNS (Holdings) Limited]]></category>
		<category><![CDATA[WSO]]></category>
		<category><![CDATA[WSTL]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[Xilinx Inc.]]></category>
		<category><![CDATA[XLNX]]></category>
		<category><![CDATA[XRX]]></category>
		<category><![CDATA[XXIA]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>
		<category><![CDATA[ZION]]></category>
		<category><![CDATA[Zions BanCorporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79251</guid>
		<description><![CDATA[Earnings Preview 7/15/11 Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are in the S&#38;P 500. By next Friday we should have a very good handle on how the overall earnings season will go. The firms reporting this week are sort of like a who&#8217;s who of U.S. industry including: Apple (AAPL), American Express (AXP), Bank of America (BAC), Caterpillar (CAT), General Electric (GE), International Business Machines (IBM), Intel (INTC), McDonald&#8217;s (MCD), Schlumberger (SLB) and Verizon (VZ). That is an interesting cross section of U.S. business. We have a relatively light economic data calendar, so earnings should be front and center, along with the sovereign debt situations on both ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Announces Viibryd Launch</title>
		<link>http://www.stockbloghub.com/2011/07/06/frx-forest-laboratories-announces-viibryd-launch/78478</link>
		<comments>http://www.stockbloghub.com/2011/07/06/frx-forest-laboratories-announces-viibryd-launch/78478#comments</comments>
		<pubDate>Wed, 06 Jul 2011 19:25:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78478</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) recently announced the launch of Viibryd (vilazodone HCl) tablets in the US. Viibryd, which is approved for the treatment of adults with major depressive disorder, is available at pharmacies across the US. FDA Approval in Jan 2011 Viibryd received approval from the US Food and Drug Administration (FDA) on Jan 21, 2011. Viibryd became a part of Forest Lab’s portfolio following its acquisition of Clinical Data earlier this year. Besides Viibryd, Forest Labs also gained access to other candidates including phase III candidate, Stedivaze, through this acquisition. Stedivaze is in development as a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI). The company expects to launch this product by 2014. We believe Forest Labs is well-positioned for the commercialization of Viibryd given its strong presence ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/frx-forest-laboratories-announces-viibryd-launch/78478/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Seeks FDA Nod for COPD Drug</title>
		<link>http://www.stockbloghub.com/2011/07/01/frx-forest-laboratories-seeks-fda-nod-for-copd-drug/78228</link>
		<comments>http://www.stockbloghub.com/2011/07/01/frx-forest-laboratories-seeks-fda-nod-for-copd-drug/78228#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:30:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78228</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and partner Almirall, S.A. recently announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for their chronic obstructive pulmonary disease (COPD) candidate, aclidinium bromide. Aclidinium bromide is a long-acting inhaled antimuscarinic agent which has been developed for the treatment of COPD. Top-Line Results Presented in Jan 2011 Forest Labs and Almirall had announced positive top-line data on aclidinium earlier this year. Results were presented from a pivotal phase III study (ATTAIN) that compared the safety and efficacy of aclidinium bromide (200?g and 400?g dosed twice daily) with placebo. Results from the six month double-blind placebo-controlled ATTAIN study, which was conducted in 828 patients with moderate to severe COPD, showed that aclidinium achieved its primary as well as secondary ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/frx-forest-laboratories-seeks-fda-nod-for-copd-drug/78228/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer&#8217;s Lyrica Holds Promise</title>
		<link>http://www.stockbloghub.com/2011/06/26/pfe-pfizers-lyrica-holds-promise/77400</link>
		<comments>http://www.stockbloghub.com/2011/06/26/pfe-pfizers-lyrica-holds-promise/77400#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:31:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77400</guid>
		<description><![CDATA[Pfizer Inc. (PFE) recently presented positive top-line data on its blockbuster drug, Lyrica. Pfizer said that Lyrica met the primary endpoint in a study that was being conducted in patients with chronic central neuropathic pain following traumatic spinal cord injury. Patients participating in the double-blind, placebo-controlled, parallel group, multi-center study (Study A0081107) were randomized to receive Lyrica or placebo. Initial results showed that Lyrica demonstrated positive efficacy in reducing central neuropathic pain following spinal cord injury compared to placebo. Pfizer will analyze the data further. Pfizer has been working on expanding Lyrica’s label for additional indications. Lyrica has experienced a very strong ramp since its introduction. Total Lyrica sales in 2010 were $3.0 billion. The product is approved in 110 countries and regions for indications like diabetic nerve pain, pain ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/pfe-pfizers-lyrica-holds-promise/77400/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76322</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253#comments</comments>
		<pubDate>Tue, 14 Jun 2011 15:03:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76253</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Labs Fourth Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/18/frx-forest-labs-fourth-quarter-2011-earnings-preview/71631</link>
		<comments>http://www.stockbloghub.com/2011/04/18/frx-forest-labs-fourth-quarter-2011-earnings-preview/71631#comments</comments>
		<pubDate>Mon, 18 Apr 2011 14:41:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71631</guid>
		<description><![CDATA[Forest Labs (FRX) is all set to announce its fourth quarter and fiscal 2011 results on April 19. The Zacks Consensus Estimate for the fourth quarter is $1.07, representing a year-over-year increase of 28.9%. Meanwhile, the Zacks Consensus Estimate for fiscal 2011 is $4.35, representing a year-over-year increase of 23.9%. Third Quarter Fiscal 2011 Highlights Forest Labs reported strong earnings in the third quarter, beating the Zacks Consensus Estimate by a huge margin. Earnings came in at $1.34 for the third quarter of fiscal 2011, easily beating the Zacks Consensus Estimate of $0.99 and the year-earlier earnings of $0.97. Strong Namenda sales, lower expenses and lower share count boosted earnings. Total revenues increased 5.8% to $1.13 billion with net sales increasing 6.7% to $1.06 billion. Total revenues topped the Zacks ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/frx-forest-labs-fourth-quarter-2011-earnings-preview/71631/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204</link>
		<comments>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204#comments</comments>
		<pubDate>Sat, 02 Apr 2011 15:18:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70204</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $25.00 after the company&#8217;s fourth quarter and fiscal year 2010 financial results. Theravance’s fourth quarter 2010 loss per share of 25 cents was narrower than both the Zacks Consensus Estimate for a loss of 28 cents and the year-ago loss of 35 cents per share. The earnings improvement was driven by a better top-line performance and lower research and development costs. Revenue at Theravance increased more than 80% over the prior year to $6.9 million. Revenue was also slightly above the Zacks Consensus Revenue Estimate of $6 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest potential in the company’s pipeline, which ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMAT) Stock Market News for February 23, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/02/23/amat-stock-market-news-for-february-23-2011-market-news/67429</link>
		<comments>http://www.stockbloghub.com/2011/02/23/amat-stock-market-news-for-february-23-2011-market-news/67429#comments</comments>
		<pubDate>Wed, 23 Feb 2011 14:53:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor Equipment & Materials]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AMAT]]></category>
		<category><![CDATA[Applied Materials Inc.]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bhp Billiton Limited]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[CLDA]]></category>
		<category><![CDATA[Clinical Data Inc]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's Inc.]]></category>
		<category><![CDATA[MEMC Electronic Materials Inc.]]></category>
		<category><![CDATA[Micron Technology Inc.]]></category>
		<category><![CDATA[MU]]></category>
		<category><![CDATA[NVDA]]></category>
		<category><![CDATA[NVIDIA Corporation]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>
		<category><![CDATA[Wal-Mart Stores Inc.]]></category>
		<category><![CDATA[WFR]]></category>
		<category><![CDATA[WMT]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67429</guid>
		<description><![CDATA[The fear gauge Volatility Index (VIX) surged to its highest level since May last year and benchmark indices suffered sharp declines on Tuesday. Unrest in the Middle East and North Africa continued as immediately after the overthrow of leaders in Egypt and Tunisia, demonstrators in Bahrain, Libya and Algeria put forward similar demands. Libya has the largest oil reserves in Africa and Bahrain is next only to Saudi Arabia when it comes to oil reserves. The situation has sparked concern over oil prices and crude prices surged to their highest level in 2.5 years. The trend of rising markets now seems to be suffering a setback. On Tuesday, the Dow fell 1.44% and closed at 12,212.79. The S&#38;P 500 was down 2.05% to 1,315.44 and the Nasdaq closed at 2,756.44, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/23/amat-stock-market-news-for-february-23-2011-market-news/67429/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BHP) Company News for February 23, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/02/23/bhp-company-news-for-february-23-2011-corporate-summary/67430</link>
		<comments>http://www.stockbloghub.com/2011/02/23/bhp-company-news-for-february-23-2011-corporate-summary/67430#comments</comments>
		<pubDate>Wed, 23 Feb 2011 14:52:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Industrial Metals & Minerals]]></category>
		<category><![CDATA[Barnes & Noble Inc.]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bhp Billiton Limited]]></category>
		<category><![CDATA[BKS]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[CLDA]]></category>
		<category><![CDATA[Clinical Data Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HK]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Petrohawk Energy Corporation]]></category>
		<category><![CDATA[Questar Corporation]]></category>
		<category><![CDATA[STR]]></category>
		<category><![CDATA[Wal-Mart Stores Inc.]]></category>
		<category><![CDATA[WMT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67430</guid>
		<description><![CDATA[• Wal-Mart (NYSE:WMT) reported Q4 EPS of $1.34, ahead of the Zacks Consensus Estimate of $1.31 per share • Petrohawk Energy Corp. (NYSE:HK) reported Q4 EPS of $0.11, lower than the Zacks Consensus Estimate of $0.15 per share • Questar Corp. (NYSE:STR) reported Q4 EPS of $0.36, above the Zacks Consensus Estimate of $0.31 per share • Hewlett-Packard Co. (NYSE:HPQ) reported Q1 EPS of $1.36, ahead of the Zacks Consensus Estimate of $1.29 per share • Both JPMorgan (NYSE:JPM) and Morgan Stanley (NYSE:MS) have upgraded Molycorp (NYSE:MCP) with a new target price which implies substantial upside from the current market price of shares • Book seller Barnes &#38; Noble (NYSE:BKS) has decided to suspend its dividend to conserve cash and invest in electronic books • BHP Billiton (NYSE:BHP) said it plans to buy shale gas reserves from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/23/bhp-company-news-for-february-23-2011-corporate-summary/67430/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYPB) Cypress Bioscience Reports Wider Loss</title>
		<link>http://www.stockbloghub.com/2010/11/25/cypb-cypress-bioscience-reports-wider-loss/59647</link>
		<comments>http://www.stockbloghub.com/2010/11/25/cypb-cypress-bioscience-reports-wider-loss/59647#comments</comments>
		<pubDate>Fri, 26 Nov 2010 04:18:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexza Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXA]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[MDRNA Inc]]></category>
		<category><![CDATA[MRNA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59647</guid>
		<description><![CDATA[Cypress Bioscience, Inc. (CYPB) reported a net loss of 94 cents per share in the third quarter, significantly higher than the Zacks Consensus Estimate of a loss of 33 cents and the year ago loss of 12 cents. Despite an increase in revenues, higher operating expenses led to the wider loss in the reported quarter. Quarter in Detail Third-quarter revenues came in at $8 million, well above the Zacks Consensus Estimate of $5 million and 45.3% above the year-ago revenues of $5.5 million. Third quarter revenues consisted of $7.2 million in commercial revenues and $0.8 million in revenues under collaborative agreements. Commercial revenues of $7.2 million included royalty revenues of $3.2 million and $3.6 million in co-promotion reimbursement in connection with Savella. The co-promotion amount includes a one-time fee of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/25/cypb-cypress-bioscience-reports-wider-loss/59647/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Beats Earnings Expectations &#8211; Increases Earnings Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674</link>
		<comments>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674#comments</comments>
		<pubDate>Thu, 25 Nov 2010 06:52:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58674</guid>
		<description><![CDATA[Shire plc (SHPGY) posted earnings of $1.16 per American Depositary Share (ADS) during the third quarter of 2010, beating the Zacks Consensus Estimate of 98 cents and the year-ago earnings of 49 cents per ADS. Higher revenues accounted for the strong performance. Revenues Quarterly revenues increased 31% year over year to $874 million, well above the Zacks Consensus Estimate of $847 million. Increased product sales and higher royalties helped boost revenues. Product sales went up 32% to $794 million, while royalties increased 27% to $76.5 million. Royalty revenue mainly comprises income earned on the sale of the authorized generic version of Adderall XR, 3TC and Zeffix. During the third quarter, Shire received royalties from Impax Laboratories Inc. (IPXL) for Adderall XR and from GlaxoSmithKline plc (GSK) for 3TC and Zeffix. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZO) Company News for September 21, 2010</title>
		<link>http://www.stockbloghub.com/2010/09/22/azo-company-news-for-september-21-2010/52395</link>
		<comments>http://www.stockbloghub.com/2010/09/22/azo-company-news-for-september-21-2010/52395#comments</comments>
		<pubDate>Wed, 22 Sep 2010 16:15:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Auto Parts Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AutoZone Inc.]]></category>
		<category><![CDATA[AZO]]></category>
		<category><![CDATA[Bristow Group]]></category>
		<category><![CDATA[BRS]]></category>
		<category><![CDATA[CAG]]></category>
		<category><![CDATA[ConAgra Foods]]></category>
		<category><![CDATA[COT]]></category>
		<category><![CDATA[Cott Corporation]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[DFS]]></category>
		<category><![CDATA[Discover Financial Services]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JA Solar Holdings Company Limited]]></category>
		<category><![CDATA[JASO]]></category>
		<category><![CDATA[Nabors Industries Limited]]></category>
		<category><![CDATA[NBR]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52395</guid>
		<description><![CDATA[• Nokia (NYSE:NOK) for the second time announced delivery delays of its N8 model smartphone • ConAgra (NYSE:CAG) announced worse-than-expected fiscal first quarter earnings of 34 cents a share, off estimates of 39 cents, on revenues of $2.82 billion, below estimates at $2.98 billion • AutoZone (NYSE:AZO) reported better-than-forecast sales and earnings for fiscal fourth quarter, with earnings of $5.66 ahead of Street estimates at $5.42 and revenues of $2.45 billion better than the expected $2.39 billion • Hewlett-Packard (NYSE:HPQ) ended its dispute with former CEO Hurd • Goldman Sachs (NYSE:GS) added Nabors Industries (NYSE:NBR) to its Conviction Buy List with a price target $22 • FBR reiterates an &#8220;outperform&#8221; rating on Sprint Nextel (NYSE:S), with a price target $6 • Goldman Sachs (NYSE:GS) resumed coverage of Forest Labs (NYSE:FRX), with a &#8220;neutral&#8221; rating and a price ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/22/azo-company-news-for-september-21-2010/52395/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Responds to US Food and Drug Administration Letter</title>
		<link>http://www.stockbloghub.com/2010/09/15/frx-forest-laboratories-responds-to-us-food-and-drug-administration-letter/51483</link>
		<comments>http://www.stockbloghub.com/2010/09/15/frx-forest-laboratories-responds-to-us-food-and-drug-administration-letter/51483#comments</comments>
		<pubDate>Wed, 15 Sep 2010 15:09:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=51483</guid>
		<description><![CDATA[Forest Laboratories Inc. (FRX) recently announced that it has submitted a response to the complete response letter (CRL) issued by the US Food and Drug Administration (FDA) in mid-May for Daxas (roflumilast). Forest Labs and partner, Nycomed GmbH, are looking to get Daxas approved for the treatment of reduction of chronic obstructive pulmonary disease (COPD) exacerbations associated with chronic bronchitis in patients at risk of exacerbations. Earlier this year, the FDA’s Pulmonary-Allergy Drugs Advisory committee had reviewed Forest Labs’ new drug application (NDA) for Daxas and had voted 10-5 against approving the candidate for the treatment of COPD. At that time, concerns were raised regarding the risk-benefit profile of the drug. The FDA had noted that while Daxas achieved statistical significance in clinical studies, the improvements were modest. Moreover, the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/15/frx-forest-laboratories-responds-to-us-food-and-drug-administration-letter/51483/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JAZZ) Jazz Pharmaceuticals JZP-6 Faces US Food and Drug Administration Setback</title>
		<link>http://www.stockbloghub.com/2010/08/23/jazz-jazz-pharmaceuticals-jzp-6-faces-us-food-and-drug-administration-setback/49058</link>
		<comments>http://www.stockbloghub.com/2010/08/23/jazz-jazz-pharmaceuticals-jzp-6-faces-us-food-and-drug-administration-setback/49058#comments</comments>
		<pubDate>Mon, 23 Aug 2010 22:57:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JAZZ]]></category>
		<category><![CDATA[Jazz Pharmaceuticals Inc]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49058</guid>
		<description><![CDATA[Jazz Pharmaceuticals Inc. (JAZZ) recently announced that the US Food and Drug Administration’s (FDA) joint advisory committee voted against the approval of the company’s fibromyalgia treatment, JZP-6. The agency’s Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 20-2 against the drug, saying that the risks of JZP-6 outweighed its benefits. The FDA advisory committee also asked Jazz Pharma to review the Risk Evaluation Mitigation Strategy for JZP-6. Although the agency is not required to do so, it usually follows the advice of its advisory panels. Given the negative feedback from the FDA’s advisory committees, we believe the FDA will most likely delay approval of the product. A response from the agency is due by October 11. Jazz Pharma intends to work closely with the FDA ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/23/jazz-jazz-pharmaceuticals-jzp-6-faces-us-food-and-drug-administration-setback/49058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Pharma Merger Mania is Heating Up</title>
		<link>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477</link>
		<comments>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477#comments</comments>
		<pubDate>Sat, 31 Jul 2010 16:17:01 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45477</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the healthcare sector, it’s all about pills. Lots and lots of pills. Blue pills, purple pills, sleeping pills, anti-depressants. They’re everywhere. It’s big business for Big Pharma and the companies are very good at marketing their products. Comedian Chris Rock referred to this trend, noting that drug companies keep naming symptoms until they find one that you have: Are you sad, are you lonely, are you hot, are you cold? You gotta take this pill! And they don’t even tell you what the pill does… they just keep naming symptoms. I saw a commercial the other day that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Big Pharma Has a Big Problem and Merger Mania is Heating Up</title>
		<link>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107</link>
		<comments>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107#comments</comments>
		<pubDate>Wed, 28 Jul 2010 18:53:53 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45107</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the healthcare sector, it’s all about pills. Lots and lots of pills. Blue pills, purple pills, sleeping pills, anti-depressants. They’re everywhere. It’s big business for Big Pharma and the companies are very good at marketing their products. Comedian Chris Rock referred to this trend, noting that drug companies keep naming symptoms until they find one that you have: Are you sad, are you lonely, are you hot, are you cold? You gotta take this pill! And they don’t even tell you what the pill does… they just keep naming symptoms. I saw a commercial the other day that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Settles Patent Fight</title>
		<link>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919</link>
		<comments>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919#comments</comments>
		<pubDate>Mon, 26 Jul 2010 21:35:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44919</guid>
		<description><![CDATA[Forest Laboratories Inc. (FRX) and partner Merz GmbH &#38; Co. KGaA recently entered into a patent litigation settlement agreement with about 10 companies that were seeking to launch their generic versions of Alzheimer&#8217;s drug Namenda (memantine). As per the settlement agreement, the generic version of the drug will enter the market on January 11, 2015, three months before the patent expires in April 2010. This settlement agreement is subject to review by the US government. While Forest Labs and Merz settled the litigation with Watson Pharmaceuticals Inc. (WPI), Dr. Reddy&#8217;s Laboratories Ltd. (RDY), Mylan Inc. (MYL), Teva Pharmaceutical Industries Ltd. (TEVA) and a few other companies, the dispute is still ongoing with certain other generic manufacturers. We believe Forest Labs and Merz will seek to settle with these companies as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Labs Tops Consensus Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/07/20/frx-forest-labs-tops-consensus-earnings-estimates/44133</link>
		<comments>http://www.stockbloghub.com/2010/07/20/frx-forest-labs-tops-consensus-earnings-estimates/44133#comments</comments>
		<pubDate>Tue, 20 Jul 2010 20:40:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44133</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) reported earnings per share of 95 cents for the first quarter of fiscal 2011, well above the Zacks Consensus Estimate of 86 cents and the year-earlier earnings of 87 cents. Including the impact of a charge related to investigations being carried out by the US Department of Justice (DoJ) and a new product licensing fee, earnings came in at 39 cents per share. First quarter revenues increased 5.8% to $1.07 billion, with net sales increasing 7.6% to $1 billion. While contract revenues slipped 16.6% to $39.8 million, interest income declined 42.5% to $7 million. The Quarter in Detail First quarter product revenues increased 7.6% to $1,020.1 million. Although Lexapro revenues remained flat at $565.2 million, Namenda, which is approved for the treatment of moderate and severe ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/frx-forest-labs-tops-consensus-earnings-estimates/44133/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Learns Daxas FDA Approval Delayed</title>
		<link>http://www.stockbloghub.com/2010/05/24/frx-forest-laboratories-learns-daxas-fda-approval-delayed/37723</link>
		<comments>http://www.stockbloghub.com/2010/05/24/frx-forest-laboratories-learns-daxas-fda-approval-delayed/37723#comments</comments>
		<pubDate>Mon, 24 May 2010 21:47:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37723</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) recently announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Daxas (roflumilast). Forest and partner, Nycomed, were looking to get Daxas approved for the treatment of reduction of chronic obstructive pulmonary disease (COPD) exacerbations associated with chronic bronchitis in patients at risk for exacerbations. While the agency has asked Forest and Nycomed to submit additional information and analyses, we are pleased to note that the companies have not been asked to conduct additional studies, which would have involved extra costs and time. The delay in Daxas’ approval does not come as a surprise. Earlier this year, the FDA’s Pulmonary-Allergy Drugs Advisory committee had voted 10-5 against granting approval to Daxas for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/frx-forest-laboratories-learns-daxas-fda-approval-delayed/37723/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories&#8217; Earnings Report Meets &#8211; Forward Guidance Drops</title>
		<link>http://www.stockbloghub.com/2010/04/21/frx-forest-laboratories-earnings-report-meets-forward-guidance-drops/34459</link>
		<comments>http://www.stockbloghub.com/2010/04/21/frx-forest-laboratories-earnings-report-meets-forward-guidance-drops/34459#comments</comments>
		<pubDate>Wed, 21 Apr 2010 22:20:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34459</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) reported earnings per share of 83 cents for the fourth quarter of fiscal 2010, in-line with the Zacks Consensus Estimate, and above the year-ago earnings of 76 cents. Full-year earnings came in at $3.51, up from fiscal 2009 earnings of $3.45. While fourth quarter revenues increased 9.4% to $1.06 billion, full-year revenues increased 6.9% to $4.2 billion. The Quarter in Detail Fourth quarter product revenues increased 11% to $996 million. Although Lexapro revenues grew only 1.4% to $556.3 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $297.9 million, recording a growth of 22.2% from the year-ago period. Improved patient access and increased promotional efforts should help keep Namenda sales strong. Bystolic, Forest’s beta-blocker for the treatment of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/frx-forest-laboratories-earnings-report-meets-forward-guidance-drops/34459/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Labs Earnings Preview &#8211; Third Quarter Highlights</title>
		<link>http://www.stockbloghub.com/2010/04/14/frx-forest-labs-earnings-preview-third-quarter-highlights/33718</link>
		<comments>http://www.stockbloghub.com/2010/04/14/frx-forest-labs-earnings-preview-third-quarter-highlights/33718#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:48:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33718</guid>
		<description><![CDATA[Forest Labs (FRX) is all set to announce its fourth quarter and full year fiscal 2010 results on Apr 20. The company expects to report fiscal 2010 earnings towards the higher end of its guidance range of $3.40 &#8211; $3.50 per share on revenues of $4.1 billion. Third Quarter Highlights Forest reported strong earnings of 97 cents per share in the third quarter, which topped the Zacks Consensus Estimate by 11 cents. Total revenues increased 6.7% to $1.06 billion with product revenues increasing 8.4% to $997 million. Although Lexapro sales declined 0.5% to $582.6 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $282.5 million, recording a growth of 17.3% from the year-ago period. Improved patient access and increased promotional efforts should help ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/frx-forest-labs-earnings-preview-third-quarter-highlights/33718/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Labs Gets Blow From FDA Panel</title>
		<link>http://www.stockbloghub.com/2010/04/09/frx-forest-labs-gets-blow-from-fda-panel/33338</link>
		<comments>http://www.stockbloghub.com/2010/04/09/frx-forest-labs-gets-blow-from-fda-panel/33338#comments</comments>
		<pubDate>Fri, 09 Apr 2010 21:26:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33338</guid>
		<description><![CDATA[The US Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory committee dealt a blow to Forest Labs (FRX) with the committee voting 10-5 against granting approval to Forest’s Daxas for the treatment of chronic obstructive pulmonary disease (COPD). Forest shares were down more than 13% at market close yesterday on the disappointing news reported by both Associated Press and Reuters. Earlier, MarketWatch had reported that the panel had voted 9-6 in favor of the product’s efficacy and safety. However, the final vote (10-5) was against approval based on the panel’s opinion that the benefits of Daxas were modest and not enough to outweigh the risks associated with the use of the drug. The news did not come as a surprise as documents released by the FDA earlier this week had ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/09/frx-forest-labs-gets-blow-from-fda-panel/33338/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Labs&#8217; Daxas to Get FDA Panel Review</title>
		<link>http://www.stockbloghub.com/2010/04/06/frx-forest-labs-daxas-to-get-fda-panel-review/32933</link>
		<comments>http://www.stockbloghub.com/2010/04/06/frx-forest-labs-daxas-to-get-fda-panel-review/32933#comments</comments>
		<pubDate>Tue, 06 Apr 2010 20:39:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32933</guid>
		<description><![CDATA[The US Food and Drug Administration&#8217;s (FDA) Pulmonary-Allergy Drugs Advisory Committee will be meeting on Apr 7 to review the efficacy and safety of Forest Labs&#8216; (FRX) Daxas (roflumilast), which is currently under review for the treatment of chronic obstructive pulmonary disease (COPD). Documents released by the FDA indicate that there could be some concerns regarding the efficacy of the drug. The FDA noted that while Daxas achieved statistical significance in the clinical studies, the improvements were modest. The agency is also concerned about the safety profile of the candidate. In addition to the frequent and sometimes severe gastrointestinal toxicities observed with the use of PDE4 inhibitors like Daxas, the FDA is concerned about the occurrence of psychiatric adverse events like suicide. Three people with no previous history of depression ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/06/frx-forest-labs-daxas-to-get-fda-panel-review/32933/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYPB) Cypress Bioscience&#8217;s Fourth Quarter Loss Narrows</title>
		<link>http://www.stockbloghub.com/2010/04/01/cypb-cypress-biosciences-fourth-quarter-loss-narrows/32654</link>
		<comments>http://www.stockbloghub.com/2010/04/01/cypb-cypress-biosciences-fourth-quarter-loss-narrows/32654#comments</comments>
		<pubDate>Thu, 01 Apr 2010 21:41:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32654</guid>
		<description><![CDATA[Cypress Bioscience, Inc. (CYPB) reported a net loss of 13 cents per share in the fourth quarter Incorporatedluding the impact of a $1.1 million goodwill impairment charge associated with the company’s personalized medicine services business. Excluding this charge, net loss came in at 10 cents, much better than the year-ago loss of 19 cents and the Zacks Consensus Estimate of -13 cents. Despite a significant increase in full year 2009 revenues, net loss for the full year increased to 74 cents Incorporatedluding the impact of the goodwill impairment charge, from the loss of 48 cents reported in 2008. Excluding the impact of the goodwill impairment charge, net loss for 2009 came in at 71 cents. The higher loss was due to higher operating expenses on account of costs associated with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/cypb-cypress-biosciences-fourth-quarter-loss-narrows/32654/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Announces Promising COPD Drug</title>
		<link>http://www.stockbloghub.com/2010/01/23/frx-forest-laboratories-announces-promising-copd-drug/25770</link>
		<comments>http://www.stockbloghub.com/2010/01/23/frx-forest-laboratories-announces-promising-copd-drug/25770#comments</comments>
		<pubDate>Sat, 23 Jan 2010 21:15:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25770</guid>
		<description><![CDATA[Recently, Forest Laboratories (FRX) and Spain based Almirall announced positive phase III top-line results of Forest’s pipeline candidate aclidinium, a multi dose dry-powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD). It was observed that aclidinium met its primary end point – it produced statistically significant improvement from the baseline in morning pre-dose (trough) FEV1 versus placebo at week 12. While the drug has been developed by Almirall, Forest holds the US rights. Reported adverse events were similar across the study arms, which included COPD exacerbation, dyspnea, headache and nasopharyngitis. Earlier, in 2008, Forest came out with mixed data on aclidinium from two phase III programs called ACCLAIM/COPD I &#38; II. While safety and tolerability were excellent, efficacy data was disappointing. Although the primary endpoint was met, the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/frx-forest-laboratories-announces-promising-copd-drug/25770/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Beats Earnings Expectations</title>
		<link>http://www.stockbloghub.com/2010/01/19/frx-forest-laboratories-beats-earnings-expectations/25291</link>
		<comments>http://www.stockbloghub.com/2010/01/19/frx-forest-laboratories-beats-earnings-expectations/25291#comments</comments>
		<pubDate>Tue, 19 Jan 2010 23:36:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25291</guid>
		<description><![CDATA[This morning, Forest Laboratories, Inc. (FRX), reported earnings per share of 97 cents for the third quarter of fiscal 2010, well above the Zacks Consensus Estimate of 86 cents. Total revenues increased 6.7% to $1.06 billion with product revenues increasing 8.4% to $997 million. Although Lexapro sales declined 0.5% to $582.6 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $282.5 million, recording a growth of 17.3% from the year-ago period. Improved patient access and increased promotional efforts should help keep Namenda sales strong. Bystolic, Forest’s beta-blocker for the treatment of hypertension, posted sales of $47.5 million. This was significantly higher than the year-ago sales of $21 million. Contract revenue, consisting primarily of Benicar co-promotion income Incorporatedreased 6.5% to $55.8 million. Forest’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/19/frx-forest-laboratories-beats-earnings-expectations/25291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Roche Eyes COPD Market</title>
		<link>http://www.stockbloghub.com/2010/01/11/mrk-roche-eyes-copd-market/24634</link>
		<comments>http://www.stockbloghub.com/2010/01/11/mrk-roche-eyes-copd-market/24634#comments</comments>
		<pubDate>Mon, 11 Jan 2010 22:28:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24634</guid>
		<description><![CDATA[Roche (RHHBY.PK) has entered into an alliance with the Belgian biotech company Galapagos to develop new therapies for the treatment of chronic obstructive pulmonary disease (COPD). While Galapagos will be responsible for the development of COPD targets and drug candidates for these targets, Roche will have an exclusive option to license each Galapagos development program at an early stage. On exercising the option, Roche will be responsible for further development of the drug candidates and their commercialization. As per the terms of the agreement, Galapagos will receive an upfront payment of €6 million from Roche. In addition, Galapagos is also eligible to receive another €400 million in the form of milestones as well as royalties upon the commercialization of any products covered in the agreement. This is the second major ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/11/mrk-roche-eyes-copd-market/24634/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson and Johnson Suffers Another Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014</link>
		<comments>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014#comments</comments>
		<pubDate>Thu, 31 Dec 2009 18:24:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24014</guid>
		<description><![CDATA[Johnson and Johnson (JNJ) has received yet another setback related to its pipeline candidate ceftobiprole, a broad-spectrum antibiotic ? aiming the methicillin-resistant Staphylococcus aureus (MRSA) ? for the treatment of complicated skin infections and nosocomial pneumonia. Johnson and Johnson had licensed the drug from Swiss drug company Basilea Pharmaceuticals in 2005. Johnson and Johnson received a complete response letter (CRL) from the US Food and Drug Administration (FDA), delaying the approval process further. According to the FDA, there were many flaws in the trials due to which the company has been asked to conduct new studies to evaluate the drug&#8217;s safety and effectiveness. Johnson and Johnson intends to discuss its future course of action related to ceftobiprole with the FDA shortly. The new drug application (NDA) for ceftobiprole has been ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
